Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells
- 1 May 2014
- journal article
- Published by Elsevier BV in Cellular Signalling
- Vol. 26 (5), 1030-1039
- https://doi.org/10.1016/j.cellsig.2014.01.026
Abstract
No abstract availableKeywords
Funding Information
- National Natural Scientific Foundation (30973474, 81172331)
- Natural Scientific Foundation of Heilongjiang Province (H201307)
- Youth Scientific Fund of Heilongjiang Province (QC2013C103, QC2013C098)
This publication has 43 references indexed in Scilit:
- HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progressionNature Reviews Cancer, 2011
- Differential Hypoxic Regulation of Hypoxia-Inducible Factors 1α and 2αMolecular Cancer Research, 2011
- Targeting hypoxia in cancer therapyNature Reviews Cancer, 2011
- Management of hepatocellular carcinoma: An updateJournal of Hepatology, 2011
- HIF-1 and HIF-2 Transcription Factors - Similar but Not IdenticalMolecules and Cells, 2010
- Systemic Treatment of Hepatocellular Carcinoma: Dawn of a New Era?Annals of Surgical Oncology, 2010
- Roles of hypoxia-inducible factor-1α (HIF-1α) versus HIF-2α in the survival of hepatocellular tumor spheroidsJournal of Hepatology, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- The role of hypoxia-inducible factors in tumorigenesisCell Death & Differentiation, 2008
- Hypoxia-inducible factor–2 (HIF-2) regulates hepatic erythropoietin in vivoJCI Insight, 2007